-+ 0.00%
-+ 0.00%
-+ 0.00%
INNOVENT'S PARTNER OLLIN BIOSCIENCES ANNOUNCES OVERSUBSCRIBED $330 MILLION SERIES B FINANCING TO ADVANCE GLOBAL PHASE 3 DEVELOPMENT OF IBI324 (OLN324) IN DME AND WET AMD; STUDIES COMMENCING IN SECOND HALF OF 2026
Share

Please log in to view news

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending